n-methyl-4-(n-propylthio)cyclophosphamide

N-methyl-4-(n-propylthio)cyclophosphamide is a **synthetic derivative of cyclophosphamide**, engineered as a prodrug of 4-hydroxycyclophosphamide. This compound is designed for improved chemical stability and selectively undergoes oxidative N-demethylation (primarily via hepatic cytochrome P450 enzymes) to release the active alkylating agent. The goal of these modifications is to alter and potentially expand the antitumor spectrum compared to parent cyclophosphamide. Preclinical studies demonstrated activity against leukemia and small cell lung cancer, suggesting **potential antineoplastic utility**. No marketed product or clinical use has been identified; available evidence comes from medicinal chemistry and pharmacology research[3].

Other names

n-methyl-4-(n-propylthio)cyclophosphamide